RYTM | tickerfilter.com

Fundamental analysis

21%

Profitability 25%

Dept financing 2%

Liquidity 50%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-0.44%

1 Month

3.63%

3 Months

-17.21%

6 Months

-18.13%

1 Year

45.04%

2 Year

124.87%

Key data

Stock price

$87.72

P/E Ratio

0.00

DAY RANGE

$87.19 - $90.52

EPS

-$3.11

52 WEEK RANGE

$55.31 - $122.20

52 WEEK CHANGE

$48.10

MARKET CAP

7.143 B

YIELD

N/A

SHARES OUTSTANDING

68.285 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-05-2025

BETA

1.78

PUBLIC FLOAT

AVERAGE 10 VOLUME

$581,345

AVERAGE 30 VOLUME

$843,604

Company detail

CEO: David P. Meeker
Region: US
Website: rhythmtx.com
Employees: 140
IPO year: 2017

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Rhythm Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency.

RYTM - RHYTHM PHARMACEUTICALS, INC.